# Azafaros

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/azafaros-b-v

- Industry: Pharmaceuticals
- Headquarters: Leiden, Netherlands
- Website: www.azafaros.com
- Total disclosed funding: $176M
- Latest round: Series B (May 13, 2025)
- Investors on record: 7

## About

Based in the Netherlands, Azafaros B.V. is a biotechnology firm focused on developing innovative therapies for lysosomal storage disorders, particularly aiming to improve treatment outcomes for patients with rare diseases.Founded in 2018, Azafaros B.V. operates out of Leiden, Netherlands, concentrating on therapies for lysosomal storage disorders. The company has successfully completed 3 deals, with its latest funding round being a Series B in which it raised EUR 132.00 mn on May 13, 2025, led by Jeito Capital with participation from other investors like Forbion and Schroders Capital. The firm is currently headed by CEO Stefano Portolano.Azafaros B.V. specializes in the development of innovative therapies for lysosomal storage disorders, focusing on its lead clinical candidate, nizubaglustat. This orally available azasugar targets the central nervous system to modulate the metabolism of glycosphingolipids, essential for managing key disease pathways. The company addresses conditions such as Niemann-Pick disease Type C and GM1/GM2 gangliosidoses through a unique dual mode of action, serving patients and healthcare providers primarily in Europe and North America.Azafaros generates revenue through strategic partnerships and collaborations that support its clinical programs. These transactions typically involve agreements with healthcare institutions and pharmaceutical companies, which include upfront payments, milestone payments tied to clinical successes, and royalties on future sales of approved products. The company is poised to deliver its flagship product, nizubaglustat, with plans for market entry following successful clinical trials.Azafaros plans to utilize the recent EUR 132.00 mn Series B funding to further develop its drug, nizubaglustat. The company is targeting expansion into new markets, focusing on regions that require advanced therapeutic solutions for rare diseases. As part of its growth strategy, Azafaros aims to enhance its research and development efforts, contributing to the advancement of its clinical programs and potentially introducing new products to the market in the near future.

## Funding rounds

- Series B, May 13, 2025, $149M — Schroders Capital, Pictet Group, Seroba, Forbion, BioGeneration Ventures, Jeito Capital
- Series A, Feb 6, 2020, $27M — BioMed Partners, Forbion, BioGeneration Ventures
- Seed, Jul 23, 2018 — BioGeneration Ventures

## Investors

- BioGeneration Ventures (https://capitalatlas.ai/funds/biogeneration-ventures) — Seed, Series A, Series B
- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A, Series B
- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Series B
- Pictet Group — Series B
- Seroba (https://capitalatlas.ai/funds/seroba) — Series B
- Jeito Capital (https://capitalatlas.ai/funds/jeito-capital) — Series B